Université de Lille, Faculté de Médecine, CHU de Lille, Laboratoire de Virologie/EA3610, F-59037 Lille, France.
Université de Picardie Jules Verne, CHU d'Amiens, Service d'Endocrinologie-Diabétologie-Nutrition, F-80054 Amiens, France.
Antiviral Res. 2018 Nov;159:130-133. doi: 10.1016/j.antiviral.2018.10.002. Epub 2018 Oct 2.
Group B Coxsackieviruses (CV-B) are responsible for various acute human diseases, and they are involved in chronic diseases such as type 1 diabetes. It has been reported that fluoxetine (FLX) inhibited CV-B4E2 in human cell lines in vitro. In so far as CV-B4E2 can replicate in CD1 mice, it was investigated whether FLX could inhibit CV-B4E2 in vitro and in vivo in mouse systems. When 5.5 μM FLX was added to CV-B4E2-infected Min-6 cell (murine pancreas beta cell line) cultures, the virus-induced cytopathic effect was inhibited. In this system and in CV-B4E2-infected CD1 mouse pancreatic organotypic cultures treated with FLX the levels of infectious particles in supernatant fluids were below the limit of detection of the assay. The administration of FLX (10 mg/kg/day) by intraperitoneal route resulted in significant reduced levels of infectious particles in heart and pancreas of mice inoculated with CV-B4E2 by the same route. In conclusion FLX can inhibit CV-B4 in vitro and in vivo in mouse systems, additional studies are needed to investigate further the potential value of FLX to combat CV-B4 infections and to treat CV-B4-induced diseases.
B 组柯萨奇病毒（CV-B）可引起多种人类急性疾病，并与 1 型糖尿病等慢性疾病有关。有报道称氟西汀（FLX）可在体外抑制人细胞系中的 CV-B4E2。鉴于 CV-B4E2 可在 CD1 小鼠中复制，因此研究了 FLX 是否可在小鼠系统中体外和体内抑制 CV-B4E2。当将 5.5μM 的 FLX 添加到感染 CV-B4E2 的 Min-6 细胞（鼠胰腺β细胞系）培养物中时，病毒诱导的细胞病变效应受到抑制。在该系统以及用 FLX 处理的感染 CV-B4E2 的 CD1 鼠胰腺器官型培养物中，上清液中感染性颗粒的水平低于检测限。通过腹腔内途径给予 FLX（10mg/kg/天），可使通过相同途径接种 CV-B4E2 的小鼠心脏和胰腺中的感染性颗粒水平显著降低。总之，FLX 可在体外和体内抑制小鼠系统中的 CV-B4，需要进一步研究 FLX 抑制 CV-B4 感染和治疗 CV-B4 诱导疾病的潜在价值。
